Treatment Guideline: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer - Updated in 2026

The Breast Oncology Center at Dana-Farber Cancer Institute held multidisciplinary meetings to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.